Featured Research

from universities, journals, and other organizations

Study Points To Possible Gene Therapy Cure For Hemophilia

Date:
June 11, 1999
Source:
University Of North Carolina School Of Medicine
Summary:
New results from gene therapy studies at the University of North Carolina at Chapel Hill may lead to an effective long-term treatment, if not a cure, for hemophilia A, the most common form of this inherited blood disease.

CHAPEL HILL, N.C. - New results from gene therapy studies at the University of North Carolina at Chapel Hill may lead to an effective long-term treatment, if not a cure, for hemophilia A, the most common form of this inherited blood disease.

Related Articles


Studies in mice involved attaching a cloned gene responsible for human clotting factor VIII - a protein severely deficient in people with hemophilia A - to a genetically engineered virus called AAV. A single injection of the virus led to a gradual increase in blood levels of factor VIII, which have remained stable for 11 months.

"This is the first result in animals demonstrating the efficacy of this approach to hemophilia A," says Dr. Christopher E. Walsh, assistant professor of medicine at UNC-CH School of Medicine and clinical director of the university's Gene Therapy Center. "The goal is one dose -- that essentially one dose delivered by gene therapy would be all that's needed to be physiologically cured of future bleeds."

On June 9, in Washington, D.C., Walsh and his colleague, Dr. Hengjun Chao, a postdoctoral researcher at the center, will present the new findings to the American Society of Gene Therapy.

The UNC-CH researchers point out that earlier gene transfer attempts in mice using other virus systems resulted in higher blood levels of factor VIII. These, however, proved short-lived, lasting from just a few days to a few months. Moreover, those treatments proved highly toxic to the liver, which is the source of the clotting factor.

"Compared with other viral vectors - retrovirus and adenovirus - AAV has its advantages: it is nonpathogenic, non-toxic, and provides very long-term expression of the factor VIII protein," Chao says.

The UNC-CH researchers were able to achieve factor VIII levels up to 20 percent of normal in a strain of healthy mice and factor VIII "knockout mice," a strain genetically bred without the gene for the clotting protein.

"Although the [blood] levels of factor VIII are not at 100 percnet using AAV gene transfer, they would be clinically beneficial to patients with hemophilia A," Walsh says. He notes that people with severe hemophilia typically have factor VIII blood levels less than 1 percent of normal. "Those patients start spontaneous bleeding into joints and muscle and need frequent transfusion. And those are the bulk of hemophilia patients with inadequate factor VIII levels."

Thus, the results in mice translated into humans would mean that the sustained factor VIII levels obtained through AAV gene therapy would dramatically reduce spontaneous bleeding and its manifestations.

"So for most of the patients, if you can get their factor VIII levels to greater than 5 percent constantly, they wouldn't have joint disease, the chronic arthritis, the deformities, and other problems hemophilia patients go through by the time they're in their twenties and thirties," says Walsh.

The researchers will soon test AAV factor VIII gene transfer in dogs using a cloned canine factor VIII gene. This will reduce the likelihood that the animal's immune system will mount an attack on the protein, which sees it as "foreign."

"We can probably get levels much higher because presumably the immune response to that protein would be limited," Walsh says.

Of the roughly 30,000 people with hemophilia in the United States, about 80 percent have hemophilia A. Now that genes for the major clotting factors have been cloned, the proteins are made in cell lines, and purified products can be manufactured in vast quantities -- without the HIV and hepatitis risk that were associated with the earlier clotting proteins made from blood products. Still, treatment is costly. An average hemophilia A patient uses about $3,000 to $4,000 a dose, which lasts about 12 hours.

"And many times, even with that, they'll have bleeding that will not stop and the factor must be given frequently," Walsh says. "That's why our goal is one dose only."


Story Source:

The above story is based on materials provided by University Of North Carolina School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina School Of Medicine. "Study Points To Possible Gene Therapy Cure For Hemophilia." ScienceDaily. ScienceDaily, 11 June 1999. <www.sciencedaily.com/releases/1999/06/990611075038.htm>.
University Of North Carolina School Of Medicine. (1999, June 11). Study Points To Possible Gene Therapy Cure For Hemophilia. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/1999/06/990611075038.htm
University Of North Carolina School Of Medicine. "Study Points To Possible Gene Therapy Cure For Hemophilia." ScienceDaily. www.sciencedaily.com/releases/1999/06/990611075038.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins